In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request.
Detailed information related to Lundbeck’s financial performance. Contact Palle Olesen, VP Investor Relations. + 45 3083 2426
A global pharmaceutical company specialized in brain diseases.
Lundbeck seeks an open dialogue with the press. For general press enquiries, please call + 45 3643 4000